Evidence map›Paper›PMID 36571667›Full record

SynthesisInternational urology and nephrology2023

Effect of finerenone on cardiovascular events in kidney disease and/or diabetes: a meta analysis of randomized control trials.

Yuhan Zhu, Maifen Song, Tengfei Chen, Zhihai Yang, Yanyan Liu

Abstract readMeta-Analysis
PubMed Publisher
In one paragraph

Synthesis in International urology and nephrology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 5 pooled it
2.1field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 5 syntheses or guidelines pooled it, 15 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Review
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Review
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Yuhan ZhuBeijing Hospital of Traditional Chinese Medicine, Capital Medical University, Intensive Care Unit department, No. 23, Mei Shu Guan Hou Jie, Dongcheng District, Zip Code: 100010, Beijing, China. 15120068727@163.com.
Maifen SongBeijing Hospital of Traditional Chinese Medicine, Capital Medical University, Intensive Care Unit department, No. 23, Mei Shu Guan Hou Jie, Dongcheng District, Zip Code: 100010, Beijing, China.
Tengfei ChenBeijing Hospital of Traditional Chinese Medicine, Capital Medical University, Intensive Care Unit department, No. 23, Mei Shu Guan Hou Jie, Dongcheng District, Zip Code: 100010, Beijing, China.
Zhihai YangBeijing Hospital of Traditional Chinese Medicine, Capital Medical University, Intensive Care Unit department, No. 23, Mei Shu Guan Hou Jie, Dongcheng District, Zip Code: 100010, Beijing, China.
Yanyan LiuYEDA Hospital, Yantai, China. alienstougao1@163.com.
Beijing Hospital of Traditional Chinese Medicine · CNCapital Medical University · CNYantaishan Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo evaluate the effect of finerenone on cardiovascular events in Kidney Disease and/or Diabetes.

methodsThe ClinicalTrials.gov, Medline, EMBASE, Web of Science, Cochrane Library databases were systematically searched from the inception dates to December 20, 2021 in order to identify randomized controlled trials that evaluated the effect of finerenone on cardiovascular events in Kidney Disease and/or Diabetes, without language restriction. This meta-analysis collected data from 7 randomized clinical trials that evaluated the effect of finrrenone in 15,618 patients with kidney disease and/or diabetes. Risk of bias was assessed by Cochrane Risk of Bias Assessment Tool. Inconsistency among trial results was assessed by I

resultsA total of 7 randomized controlled trials involving 15,618 fulfilled the inclusion criteria. The outcomes of this meta-analysis presented that finerenone significantly reduced the death from any cause (95% CI 0.82-0.99; P = 0.031), risk of heart failure (95% CI 0.67-0.92; P = 0.002) among patients with kidney disease and/or diabetes when compared to control group. Besides, finerenone could not reduce the incidence of death from cardiovascular, myocardial infarction and hospitalization for any cause among patients with kidney disease and/or diabetes (p > 0.05). In terms of safety, finerenone shared the same risk of total advent events with placebo among patients with kidney disease and/or diabetes (p > 0.05). However, finerenone had higher risk of study-drug-related advent events than placebo among patients with kidney disease and/or diabetes (95% CI 1.27-1.48; P < 0.001).

conclusionsIn patients with kidney disease and/or diabetes, treatment with finerenone resulted in lower risk of death from any cause and heart failure than placebo. However, the study-drug-related advent events also increased significantly at the same time.

Indexed as

Cardiovascular DiseasesDiabetes Mellitus, Type 2Diabetic NephropathiesHeart FailureMyocardial InfarctionHumansRandomized Controlled Trials as TopicCardiovascular eventsDiabetesFinerenoneKidney diseaseMeta analysis

Identifiers

PMID36571667
OpenAlexW4312194956

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.